Obesity Paradox and Heart Failure
Overview
Affiliations
Background: There is scientific consensus that obesity increases the risk of cardiovascular diseases (CVD), including heart failure (HF). However, in CVD, many studies observed greater survival in overweight or class 1 obesity individuals. This counterintuitive observation was termed "obesity paradox" (OP).
Objective And Methods: This article is a narrative overview of the relationship between OP and CVD, particularly HF. The sources used were MEDLINE/PubMed, CINAHL, EMBASE, and Cochrane Library, from 2001 to 31 May 2020, exception for a 1983 work of historical importance. Studies reporting association and prognostic impact of obesity in HF and the impact of body composition on cardiac structure and myocardial function in obesity were also included in this review. In addition, we examined references from the retrieved articles and explored several related websites. Ultimately, we chose 79 relevant documents. Fifty-three were specifically focused on OP and HF.
Results: In this review, we made a summary of the evidence coming from a series of studies investigating OP. Many of these studies do not take into consideration or underestimate some of the more important morpho-functional variables of patients suffering from HF: among these, body composition and visceral adiposity, sarcopenic obesity, muscle fitness (MF), and cardiorespiratory fitness (CRF). A high body mass index (BMI) represents a risk factor for HF, but it also seems to exert a protective effect under certain circumstances. Fat distribution, lean mass, and cardio fitness could play an essential role in determining the observed differences in the HF population.
Conclusion: BMI does not distinguish between the metabolically healthy and metabolically unhealthy obesity. The obesity impact on morbidity and premature mortality can be underestimated and, therefore, may lead to incorrect clinical courses.
Level Of Evidence: Level V, Narrative review.
Xu H, Mo R, Liu Y, Niu H, Cai X, He P Front Med (Lausanne). 2024; 11:1500995.
PMID: 39712174 PMC: 11659220. DOI: 10.3389/fmed.2024.1500995.
Lipoprotein(a) as a novel biomarker for predicting adverse outcomes in ischemic heart failure.
Zhang B, Xu Y, Huang X, Sun T, Ma M, Chen Z Front Cardiovasc Med. 2024; 11:1466146.
PMID: 39301496 PMC: 11410592. DOI: 10.3389/fcvm.2024.1466146.
Lyu L, Wang X, Xu J, Liu Z, He Y, Zhu W Cardiovasc Diabetol. 2024; 23(1):162.
PMID: 38724999 PMC: 11080126. DOI: 10.1186/s12933-024-02213-2.
Chen Y, Yin M, Fan L, Jiang X, Xu H, Zhu X Heliyon. 2024; 10(7):e28619.
PMID: 38590862 PMC: 11000018. DOI: 10.1016/j.heliyon.2024.e28619.
Ma D, Qu Y, Wu T, Liu X, Cai L, Wang Y Sci Rep. 2024; 14(1):8128.
PMID: 38584196 PMC: 10999456. DOI: 10.1038/s41598-024-58577-8.